Two Cases of HPV 16 - positive Bowenoid Papulosis Treated with Diphenylcyclopropenone Immunotherapy.
- Author:
Yoon Hee KWON
1
;
Tae Yoon KIM
;
Jong Yuk LEE
;
Chung Won KIM
;
Jong Sup PARK
;
Seung Jo KIM
Author Information
1. Department of Dermatology, Catholic University Medical College, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Bowenoid papulosis;
Human papilloma virus;
Diphenylcyclopropenone
- MeSH:
Carcinoma, Squamous Cell;
Cicatrix;
Cryosurgery;
Female;
Genitalia;
Hemorrhage;
Human papillomavirus 16*;
Humans;
Hypersensitivity, Delayed;
Immunotherapy*;
Laser Therapy;
Male;
Oncogenic Viruses;
Papilloma;
Recurrence;
Virus Diseases;
Warts
- From:Korean Journal of Dermatology
1996;34(1):160-165
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Bowenoid papulosis(BP) is characterized by multiple papules with a benign clinical course but having a histopathology of squamous cell carcinoma in situ on the external genitalia of sexually active men and women. It is well known that the Human papilloma virus(HPV) is connected with the development of BP. Out of these, HPV 16 which has been frequently found in the BP lesions is an oncogenic virus and the theory that BP might progress to intraepithelial neoplasia and advanced carcinoma has been postulated. Local destructive therapy including electrodessication, laser surgery, cryosurgery, and surgical excision is effective and produces a low recurrence rate. However, pain, bleeding, restriction in activity, and postoperative scars are inevitable with complete destruction of the multiple lesions. It has been suggested that diphenylcyclopropenone(DCP) might be a promising therapeutic agent for various viral diseases including HPV-related warts, It is a potent sensitizer which is not mutagenic and works by the induction of type IV hypersensitivity response in HPV infected tissue, leading to wart destruction. We herein, report 2 cases of HPV 16-positive BP treated with DCP immunotherapy.
